Prevalence of Duffy null and its impact on hydroxyurea in young children with sickle cell disease in the United States

Fathia Oladipupo; Joseph Stanek; Joseph Walden; Jennifer Young; Melissa J. Rose; Kathleen Nicol; Anthony Villella; Susan Creary

doi:10.1002/pbc.30945

Prevalence of Duffy null and its impact on hydroxyurea in young children with sickle cell disease in the United States

Fathia Oladipupo, Joseph Stanek, Joseph Walden, Jennifer Young, Melissa J. Rose, Kathleen Nicol, Anthony Villella, Susan Creary

Research output: Contribution to journal › Article › peer-review

Abstract

Consistent with studies showing a high prevalence of the Duffy null phenotype among healthy Black Americans, this retrospective study found that Duffy null was present in >75% of a young and contemporary cohort of children with sickle cell disease (SCD) in the United States. Despite the potential for this phenotype to impact absolute neutrophil counts, hydroxyurea (HU) dosing, and outcomes, it was not associated with being prescribed a lower HU dose or having increased acute SCD visits early in the HU treatment course. Future studies are needed to confirm these findings in older children with SCD.

Original language	English
Article number	e30945
Journal	Pediatric Blood and Cancer
Volume	71
Issue number	6
DOIs	https://doi.org/10.1002/pbc.30945
State	Accepted/In press - 2024

Keywords

hydroxyurea
outcomes research
sickle cell anemia
sickle cell disease

Access to Document

10.1002/pbc.30945

Cite this

@article{058617ef06ad425190f29b8f69b90570,

title = "Prevalence of Duffy null and its impact on hydroxyurea in young children with sickle cell disease in the United States",

abstract = "Consistent with studies showing a high prevalence of the Duffy null phenotype among healthy Black Americans, this retrospective study found that Duffy null was present in >75% of a young and contemporary cohort of children with sickle cell disease (SCD) in the United States. Despite the potential for this phenotype to impact absolute neutrophil counts, hydroxyurea (HU) dosing, and outcomes, it was not associated with being prescribed a lower HU dose or having increased acute SCD visits early in the HU treatment course. Future studies are needed to confirm these findings in older children with SCD.",

keywords = "hydroxyurea, outcomes research, sickle cell anemia, sickle cell disease",

author = "Fathia Oladipupo and Joseph Stanek and Joseph Walden and Jennifer Young and Rose, {Melissa J.} and Kathleen Nicol and Anthony Villella and Susan Creary",

note = "Publisher Copyright: {\textcopyright} 2024 Wiley Periodicals LLC.",

year = "2024",

doi = "10.1002/pbc.30945",

language = "English",

volume = "71",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

number = "6",

}

TY - JOUR

T1 - Prevalence of Duffy null and its impact on hydroxyurea in young children with sickle cell disease in the United States

AU - Oladipupo, Fathia

AU - Stanek, Joseph

AU - Walden, Joseph

AU - Young, Jennifer

AU - Rose, Melissa J.

AU - Nicol, Kathleen

AU - Villella, Anthony

AU - Creary, Susan

PY - 2024

Y1 - 2024

N2 - Consistent with studies showing a high prevalence of the Duffy null phenotype among healthy Black Americans, this retrospective study found that Duffy null was present in >75% of a young and contemporary cohort of children with sickle cell disease (SCD) in the United States. Despite the potential for this phenotype to impact absolute neutrophil counts, hydroxyurea (HU) dosing, and outcomes, it was not associated with being prescribed a lower HU dose or having increased acute SCD visits early in the HU treatment course. Future studies are needed to confirm these findings in older children with SCD.

AB - Consistent with studies showing a high prevalence of the Duffy null phenotype among healthy Black Americans, this retrospective study found that Duffy null was present in >75% of a young and contemporary cohort of children with sickle cell disease (SCD) in the United States. Despite the potential for this phenotype to impact absolute neutrophil counts, hydroxyurea (HU) dosing, and outcomes, it was not associated with being prescribed a lower HU dose or having increased acute SCD visits early in the HU treatment course. Future studies are needed to confirm these findings in older children with SCD.

KW - hydroxyurea

KW - outcomes research

KW - sickle cell anemia

KW - sickle cell disease

UR - http://www.scopus.com/inward/record.url?scp=85187435970&partnerID=8YFLogxK

U2 - 10.1002/pbc.30945

DO - 10.1002/pbc.30945

M3 - Article

C2 - 38462769

AN - SCOPUS:85187435970

SN - 1545-5009

VL - 71

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 6

M1 - e30945

ER -

Prevalence of Duffy null and its impact on hydroxyurea in young children with sickle cell disease in the United States

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this